Terkko Navigator / Prostate Cancer and Prostatic Diseases

Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only

Statins and prostate cancer—hype or hope? The epidemiological perspective

Predictive role of node-rads score in patients with prostate cancer candidates for radical prostatectomy with extended lymph node dissection: comparative analysis with validated nomograms

The role of preoperative prostatic shape in the recovery of urinary continence after robotic radical prostatectomy: a single cohort analysis

Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study

Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy

Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan

The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)

Diagnostic value of multiparametric MRI in detecting residual or recurrent prostate cancer after high-intensity focused ultrasound

Lifestyle and sociodemographic factors associated with treatment choice of clinically localized prostate cancer in an equal access healthcare system

Correction: The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study

High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments

Real-world use of MRI for risk stratification prior to prostate biopsy

PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer

Correction: Germline alterations among Hispanic men with prostate cancer

Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscape

Human herpesvirus 8 infection is associated with prostate cancer among IFNL4-ΔG carriers

One step closer between dietary pattern and cancer prevention

The impact of PSMA PET on the treatment and outcomes of men with biochemical recurrence of prostate cancer: a systematic review and meta-analysis

Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors ± androgen deprivation therapy: a pharmacovigilance study

LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial

The role of COVID-19 in prostate tissue inflammation: first pathological evidence

The differential diagnostic value of dual-phase 18F-DCFPyL PET/CT in prostate carcinoma

Gut environment changes due to androgen deprivation therapy in patients with prostate cancer

Dietary inflammatory index and prostate cancer risk: MCC-Spain study

Accuracy of SelectMDx compared to mpMRI in the diagnosis of prostate cancer: a systematic review and diagnostic meta-analysis

Correction: Estimating patient health in prostate cancer treatment counseling

The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy

Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies

Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial

The impact of a fasting mimicking diet on the metabolic health of a prospective cohort of patients with prostate cancer: a pilot implementation study

Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer

Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men

Annual Acknowledgement of Manuscript Reviewers

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer

Selective Bone Scan staging for patients with Prostate cancer: do absolute categories really make sense?

Correction to: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer

Serendipity for the intervention of COVID-19 and prostatic adenocarcinoma (PaC)

Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature

Long term genitourinary toxicity following curative intent intensity-modulated radiotherapy for prostate cancer: a systematic review and meta-analysis

Prostate arterial chemoembolization for treatment of refractory hematuria and urinary retention in patients with localized advanced prostate cancer

Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men

Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes

Correction: Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning

Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer

Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada

Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer – A propensity score analysis

Racial disparities in treatment delay among younger men with prostate cancer

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)

More evidence that physical activity is beneficial for prostate cancer